ERAS and breast carcinoma: Although ERAS expression was not clearly correlated with the molecular phenotype of breast cancer (p = 0.058, Fig. 8e), its over-expression was significantly associated with distant metastasis (p = 0.05, Fig. 8e) and reduced metastasis-free survival (p = 0.047, Supplementary Fig. S5) suggesting that ERAS expression could be considered as a poor prognosis biomarker in breast cancer.